iBio appoints Eef Schimmelpennink to its Board of Directors

– USA, TX –  iBio, Inc. (NYSEAMERICAN: IBIO), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Eef Schimmelpennink to its Board of Directors, effective immediately.

“Eef has a strong history of success leading companies with novel protein expression platforms to develop and commercialize biopharmaceutical products,” said Chairman and CEO, Tom Isett. “He is joining our team at an opportune time, given we are adding our own in-house drug discovery capabilities to our existing contract development and manufacturing services, similar to what Eef did in his most recent leadership role at Pfenex.”

About Eef Schimmelpennink

In an executive leadership career spanning more than 20 years, Eef Schimmelpennink has applied his strategic and functional expertise across corporate development, commercial operations, manufacturing, and R&D to help build and scale several global public and private biopharmaceutical businesses. Recently, he served as CEO of Pfenex Inc., an NYSEA-listed company which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million (including contingent value rights) in October 2020. Previously, Mr. Schimmelpennink served as CEO of Alvotech Ehf, a global biopharmaceutical company focused on becoming a leader in the biosimilar monoclonal antibody market. Before joining Alvotech, he held a variety of progressive roles with Pfizer Inc., Hospira, Inc., Synthon BV, and Numico NV.

Mr. Schimmelpennink holds a Masters in Bioprocess Engineering from the Wageningen University in the Netherlands.

Mr. Schimmelpennink commented, “I am honored to join iBio’s Board and look forward to working with my talented colleagues as the Company continues to harness the power of its unique plant-based FastPharming System® to help reduce drug development times and costs, and, importantly, to help rapidly develop its own biopharmaceutical candidates to address unmet medical needs in human health and veterinary medicine.”

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bio-inks, and other proteins. iBio is developing proprietary products which include biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services for advanced recombinant protein design.

For more information: https://www.ibioinc.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team